Periorbital dermatitis as a side effect of topical dorzolamide

The British Journal of Ophthalmology
Y M DelaneyS Powell

Abstract

To report periorbital dermatitis as a late side effect of topical dorzolamide hydrochloride (Trusopt), a drug used to reduce intraocular pressure. A retrospective study of 14 patients who developed periorbital dermatitis while using topical dorzolamide hydrochloride was undertaken. Six patients underwent patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and the preservative benzalkonium chloride. The periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing dorzolamide hydrochloride therapy. 13 patients had used preserved topical beta blocker treatment for a mean period of 34.2 months without complication before the introduction of dorzolamide. In eight (57.1%) the dermatitis resolved completely after discontinuing dorzolamide but in six (42.9%) resolution of the dermatitis did not occur until the concomitant preserved beta blocker was stopped and substituted with preservative free drops. Patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and benzalkonium chloride was negative. These findings suggest that dorzolamide can cause severe periorbital dermatitis. Although the dermatitis may resolve when dorzolamide is discontinued, this does not always occur and in some patie...Continue Reading

References

Aug 1, 1991·Contact Dermatitis·N CameliA Tosti
Apr 1, 1986·Contact Dermatitis·C RomagueraJ Vilaplana
Apr 1, 1986·Contact Dermatitis·J M Fernandez-VozmedianoA Carrascosa-Cerquero
Jul 1, 1995·Contact Dermatitis·V di LerniaG Bisighini
Jul 1, 1995·Contact Dermatitis·V ZucchelliA Tosti
Feb 1, 1993·Contact Dermatitis·B F O'Donnell, I S Foulds
Apr 1, 1997·Contact Dermatitis·F GarciaR Perez
Dec 31, 1997·Contact Dermatitis·R A Herbst, H I Maibach
Nov 17, 1998·Contact Dermatitis·K Aalto-Korte
Apr 28, 1999·American Journal of Ophthalmology·A KonowalR J Epstein
Jul 23, 1999·Contact Dermatitis·S ErdmannH F Merk

❮ Previous
Next ❯

Citations

Dec 5, 2002·Pharmacoepidemiology and Drug Safety
Nov 26, 2002·The British Journal of Ophthalmology·S DavaniJ-P Kantelip
Feb 3, 2007·Ophthalmology·Vijay HegdeH Ahluwalia
Apr 8, 2004·The Australasian Journal of Dermatology·Raymond J MullinsBish Dutta
Feb 19, 2008·Contact Dermatitis·Nicolas KlugerNadia Raison-Peyron
Sep 1, 2007·European Journal of Cancer Care·B Melichar, I Nemcová
Sep 16, 2011·Expert Opinion on Pharmacotherapy·Marina PapadiaCarlo E Traverso
Oct 1, 2011·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Alessandro BagnisCarlo E Traverso
Feb 6, 2019·Journal of Glaucoma·Hitomi SaitoMakoto Araie
Oct 25, 2016·Dermatitis : Contact, Atopic, Occupational, Drug·Katherine R Grey, Erin M Warshaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.